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Following publication of the original article \[[@CR1]\], the authors reported an error in Table [1](#Tab1){ref-type="table"}. In the second columns of the 'Radiology' row, 'Normal anterolateral sinus mucosa' should read 'Normal superolateral sinus mucosa'. A corrected version of Table [1](#Tab1){ref-type="table"} is included in this Correction.Table 1Summary of Key Findings of CRS PhenotypesPhenotypeCharacteristicsCCAD (IgE mediated)eCRS (AERD)Non-eCRSClinical Presentation- Young onset (teens to 20s)- Rhinitis symptoms- Smell preserved- Other atopic disease:° Childhood asthma° conjunctival symptoms, dermatitis- Mid-Life "adult" onset (30--50 yo)- Occasionally post respiratory virus- "Completely well" prior to onset or if allergic, then symptoms limited to childhood- Smell loss (corticosteroid responsive)- Antibiotic seeking- Food and alcohol induced flares- Adult onset asthma linked temporally to CRS onset.- Older onset 50 yrs.+- Female, obese- Cough- Poor corticosteroid response- "Asthma" present but often poor response to inhaled preventive therapy (corticosteroid based)Endoscopy- Middle turbinate edema- Polypoid changes from turbinates and septum- No thick mucin- Normal sinus mucosa on surgery- Polyps (small, multiple, large) from the middle meatus- Thick eosinophilic mucin- Secondary purulence- Polyps or polypoid edema- Purulent secretions- Lack of eosinophilic mucinRadiology- Central thickening of septum and turbinates, peripheral clearing (CCAD)- Mucus trapping only in sinsues- Normal superolateral sinus mucosa ("black halo")- Pan-sinusitis (Lund-Mackay 24)- Neo-osteogenesis- Pan-sinusitis (undistinguishable from eCRS)Histopathology- Elevated tissue eosinophilia- Often without activation (no eosinophil aggregates and charcot-leyden crystals)- No serum eosinophils- Elevated total and specific IgE- Elevated tissue eosinophilia (\>10eos/hpf, but often \>100eos/hpf)- Evidence of eosinophil activation (eosinophil aggregates and charcot-leyden crystals)- Serum eosinophilia- Lack of tissue eosinophilia (\< 10/HPF)Allergy- + allergy testing (dustmite/perennial allergens)- Often monoallergen-sensitized- Either negative IgE sensitization or multi-allergen sensitized- Negative skin prick, immunocap/RASTTreatment- Allergen directed immunotherapy- Endoscopic sinus surgery- Topical corticosteroid (spray or irrigation)- Systemic corticosteroid treatment (up to 2--3 times per year) if limited burden of disease- Endoscopic sinus surgery (Draf 3)- Topical corticosteroid irrigations (not sprays)For AERD:- Zileuton, Montelukast, Zafirlukast- Can take selective COX-2 inhibitors (Meloxicam)- Saline or corticosteroid irrigations- Endoscopic sinus surgery- Macrolide therapy (Clarithromycin 250 mg daily for 3 months)- Continue 3/week until 12 months if responderDifficult to control disease- Omaluzimab (anti-IgE)- Mepoluzimab (anti-IL5)- Other immune-modulating therapy (Benraluzimab, Dupiliumab, Reslizumab, etc)For AERD:- ASA desensitization (1300 mg commencement and 350--700 mg daily maintenance)- Consider re-biopsy of a patient post-surgery and post-corticosteroid based treatment if not responding and may be re-classified under this phenotype
